Becton Dickinson to break off biosciences, diagnostic solutions
Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.
Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-oriented investments and capital allocation.
Becton Dickinson outlines $14.30-$14.60 EPS target for FY25 amid planned biosciences separation
Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically aligned entities.
Becton Dickinson to Split from Bioscience and Diagnostic Solutions Arms
American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic solutions arms to become
Becton Dickinson looks to separate life sciences unit
Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business. The company has been restructuring its business portfolio in recent years,
Becton Dickinson looks to divest life sciences unit at $30 billion valuation, source says
U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of ...
Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript
At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...
Becton Dickinson & Co. stock underperforms Thursday when compared to competitors
Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.
Becton to Pare Part of Life Sciences Unit to Boost Stock (1)
Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.
BD stock slides amid earnings report, business split update
Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.
Becton Dickinson to Separate Biosciences and Diagnostic Solutions Business
BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.
Becton Dickinson to separate biosciences, diagnostic solutions business
BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...
Yahoo Finance1d
BD Stock Falls in Pre-Market Despite Q1 Earnings Beat, Gross Margin Up
Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.43 in the ...